Tumor-associated macrophages in SHH subgroup of medulloblastomas

Clinical Cancer Research

Volumn 21, Issue 6, 2015, Pages 1457-1465

  Margol, Ashley S ^a   Robison, Nathan J ^a   Gnanachandran, Janahan ^a   Hung, Long T ^a   Kennedy, Rebekah J ^a   Vali, Marzieh ^a   Dhall, Girish ^a   Finlay, Jonathan L ^a   Erdreich Epstein, Anat ^a   Krieger, Mark D ^a   Drissi, Rachid ^b   Fouladi, Maryam ^b   Gilles, Floyd H ^a   Judkins, Alexander R ^a   Sposto, Richard ^a   Asgharzadeh, Shahab ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CD14 ANTIGEN; CD163 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; PENTRAXIN 3; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA2; COLONY STIMULATING FACTOR RECEPTOR; SHH PROTEIN, HUMAN; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; BCAT1 GENE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CBLN3 GENE; CD14 GENE; CD163 GENE; CD4 GENE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; CSF1R GENE; DKK2 GENE; EOMES GENE; ERG1 GENE; EXON; FEMALE; FOXG1 GENE; GABRA5 GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GLI1 GENE; HHIP GEN; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMPG2 GENE; INFLAMMATION; KCNA GENE; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MICROARRAY ANALYSIS; MOUSE; MPP3 GENE; NONHUMAN; NPR3 GENE; ONCOGENE MYC; OTX2 GENE; PDGFRA GENE; PDLIM3 GENE; PGYL GENE; PHENOTYPE; PID1 GENE; PPP1R17 GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PTX3 GENE; PYGL GENE; REGULATORY T LYMPHOCYTE; SFRP1 GENE; SLC6A5 GENE; TERC GENE; TGFB2 GENE; TNC GENE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GENE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UNDIFFERENTIATED CARCINOMA; WIF GENE; WIF1 GENE; ANTAGONISTS AND INHIBITORS; CEREBELLUM TUMOR; GENETICS; IMMUNOLOGY; MACROPHAGE; METABOLISM; PATHOLOGY; PRESCHOOL CHILD;

BIOMARKERS, TUMOR; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION PROFILING; HEDGEHOG PROTEINS; HUMANS; INFLAMMATION; MACROPHAGES; MALE; MEDULLOBLASTOMA; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; TUMOR MICROENVIRONMENT;

EID: 84927618802     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1144     Document Type: Article

References (50)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
4. Pollard JW. Opinion: tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8.
5. Zhang Q-W, Liu L, Gong C-Y, Shi H-S, Zeng Y-H, Wang X-Z, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS ONE 2012;7:e50946.
6. Lewis CEC, Pollard JWJ. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12.
7. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol 2012;33:79-84.
8. Hussain SF. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 2006; 8:261-79.
9. Engler JR, Robinson AE, Smirnov I, Hodgson JG, Berger MS, Gupta N, et al. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS ONE 2012;7:e43339.
10. Li W, Graeber MB. The molecular pro file of microglia under the influence of glioma. Neuro Oncol 2012;14:958-78.
11. Prosniak M, Harshyne LA, Andrews DW, Kenyon LC, Bedelbaeva K, Apanasovich TV, et al. Glioma grade is associated with the accumulation and activity of cells bearing m2 monocyte markers. Clin Cancer Res 2013;19:3776-86.
12. Carvalho da Fonseca AC, Badie B.Microglia andmacrophages in malignant gliomas: recent discoveries and implications for promising therapies. Clin Dev Immunol 2013;2013:264124.
13. Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol 2012;30:3525-32.
14. Packer RJ, Sposto R, Atkins TE, Sutton LN, Bruce DA, Siegel KR, et al. Quality of life in children with primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa. Pediatr Neurosci 1987;13: 169-75.
15. Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group Study. J Clin Oncol 2001;19:3470-6.
16. Thompson MC, Fuller C. Genomics identifies medulloblastoma subgroups that are enriched for speci fic genetic alterations. J Clin Oncol 2006;24: 1924-31.
17. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE 2008;3:e3088.
18. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011;29:1408-14.
19. Cho Y-J, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011;29: 1424-30.
20. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010;468:1095-9.
21. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, et al. De finition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 2011;29:1400-7.
22. Taylor MD, Northcott PA, Korshunov A, RemkeM.Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012;23: 465-72.
23. Schwalbe EC, Lindsey JC, Straughton D, Hogg TL, Cole M, Megahed H, et al. Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res 2011;17:1883-94.
24. Parsons DW, Li M, Zhang X, Jones S, Leary RJ. The genetic landscape of the childhood cancer medulloblastoma. Science 2011;331:435-9.
25. de Haas T, Hasselt N, Troost D, Caron H, Popovic M, Zadravec-Zaletel L, et al. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression. Clin Cancer Res 2008;14:4154-60.
26. Kunder R, Jalali R, Sridhar E, Moiyadi A, Goel N, et al. Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. Neuro Oncol 2013;15: 1644-51.
27. Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics 2010;11:367.
28. Rousseeuw P. Silhouettes: A graphical aid to the interpretation and validation of cluster analysis. J Comput Appl Math 1987;20:53-65.
29. Eberhart CG, Tihan T, Burger PC. Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 2000;59: 333-7.
30. Clifford SC, Lusher ME, Lindsey JC, Langdon JA, Gilbertson RJ, Straughton D, et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 2006;5: 2666-70.
31. Constam DB, Schmid P, Aguzzi A, Schachner M, Fontana A. Transient production of TGF-β2 by postnatal cerebellar neurons and its effect on neuroplast proliferation. Eur J Neurosci 1994;6:766-78.
32. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-66.
33. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010;11: 889-96.
34. Espinosa E, Sánchez-Navarro I, Gámez-Pozo A, Marin AP, Hardisson D, Madero R, et al. Comparison of prognostic gene profiles using qRT-PCR in paraffin samples: a retrospective study in patients with early breast cancer. PLoS ONE 2009;4:e5911.
35. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, et al. Predicting outcomes for children with neuroblastoma using a multi-gene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009;10:663-71.
36. Kool M, Korshunov A, Remke M, Jones DTW, Schlanstein M, Northcott PA, et al. Molecular subgroups of medulloblastoma: an international metaanalysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012; 123:473-84.
37. Ruffell B, Affara N I, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol 2012;33:119-126.
38. Rudin CM, Hann CL, Laterra J, Yauch RL. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009;361: 1173-78.
39. Steidl C, Lee T, Shah SP, Farinha P, Han G,Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875-85.
40. Zhang BC, Gao J, Wang J, Rao ZG, Wang BC, Gao JF. Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med Oncol 2011;28: 1447-52.
41. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1: 54-67.
42. Feldhahn N, Arutyunyan A, Stoddart S, Zhang B, Schmidhuber S, Yi S-J, et al. Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia. Oncoimmunology 2012;1:618-29.
43. Jinushi M, Chiba S, Yoshiyama H. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci U S A 2011;108:12425-30.
44. Song L, Asgharzadeh S, Salo J, Engell K,Wu H-W, Sposto R, et al. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest 2009;119:1524-36.
45. Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, et al. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 2009;69:329-37.
46. Fang L-Y, Izumi K, Lai K-P, Liang L, Li L, Miyamoto H, et al. Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. Cancer Res 2013;73:5633-46.
47. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013;19:1264-72.
48. Hume DA, MacDonald KPA. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 2012;119:1810-20.
49. Robert C, Thomas L, Bondarenko I. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364: 2517-26.
50. Horton HM, Bernett MJ, Peipp M, Pong E, Karki S, Chu SY, et al. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood 2010;116:3004-12.